A Large Retrospective Cohort Study on the Risk of Alzheimer’s Disease and Related Dementias in Association with Vascular Diseases and Cancer Therapy in Men with Prostate Cancer

L. Song,X.L. Du

DOI: https://doi.org/10.14283/jpad.2023.8

2023-01-01

Abstract:BackgroundNo study was conducted on the long-term risk of Alzheimer’s disease (AD) and related dementias (ADRD) in association with vascular diseases in men with prostate cancer.ObjectivesTo determine the 26-year risk of ADRD in association with cardiovascular disease (CVD), stroke, hypertension, and diabetes in a nationwide cohort of men with prostate cancer.DesignRetrospective cohort study.SettingSurveillance, Epidemiology, and End Results (SEER) areas of the United States.Participants351,571 men diagnosed with prostate cancer at age ≥65 years.MeasurementsMain exposures were CVD, stroke, hypertension, and diabetes. Main outcome was the incidence of ADRD.ResultsThe crude 26-year cumulative incidence of any ADRD was higher in those with versus without CVD (33.80% vs 29.11%), stroke (40.70% vs 28.03%), hypertension (30.88% vs 27.31%), and diabetes (32.23% vs 28.68%). Men with CVD (adjusted hazard ratio: 1.17, 95% CI: 1.15–1.20), stroke (1.59, 1.56–1.61), hypertension (1.13, 1.11–1.14), and diabetes (1.25, 1.23–1.27) were significantly more likely to develop ADRD than those without. Patients with 4 of these vascular diseases were 161% more likely to develop ADRD (2.61, 2.47–2.76) than those without. The risk of AD (0.89, 0.87–0.91) and ADRD (0.91, 0.90–0.93) became significantly lower in men with prostate cancer who received androgen deprivation therapy as compared to those who did not after considering death as a competing risk.ConclusionsIn men with prostate cancer, vascular diseases were associated with significantly higher risks of developing ADRD. Androgen deprivation therapy was associated with a significantly decreased risk of AD in men with prostate cancer.

clinical neurology